Established in 2020, Piramal Pharma Limited (NSE: PPLPHARMA) a flagship company of the Piramal Group offers pharmaceutical products and services across a domestic and global distribution network. The company has 15 international manufacturing facilities and a global distribution network in over 100 countries. On 18th July 2023, Piramal Pharma gets approval from the Securities and Exchange Board of India (SEBI) for a rights issue, totaling up to Rs 1,050 crore.
[stock_market_widget type=”card” template=”extended” color=”#000000″ assets=”PPLPHARMA.NS” display_currency_symbol=”true” api=”yf”]
| Rights Issue Open: | Aug 8, 2023 |
| Rights Issue Close: | Aug 17, 2023 |
| Rights Record Date: | Aug 2, 2023 |
| Deemed Date of Allotment | Aug 23, 2023 |
| Renunciation of Rights Entitlements | Aug 10, 2023 |
Piramal Pharma Rights Issue 2023 Offer Details
| Rights Issue Size: | ₹1,050.00 Crores |
| Issue Price: | ₹81 per share |
| Face Value: | ₹10 per share |
| Listing on: | BSE, NSE |
| Entitlement Ratio: | 5 Rights Equity Shares for every 46 Equity Shares |
| Equity: | 12.96 Crores Equity Share |
| Letter of Offer: | Click Here |
| Application Form: | Click Here |
Terms of Payment
The full amount of Rs 81 per share has to be paid at the time of Application.
Piramal Pharma Rights Entitlement Ratio
5 Rights Equity Shares for every 46 Equity Shares holding on the record date of 2nd August 2023
Company Address:
Piramal Pharma Limited
Ground Floor, Piramal Ananta,
Agastya Corporate Park, Kamani Junction,
LBS Marg, Kurla, Mumbai 400 070
Phone: +91 22 3802 3000
Email: [email protected]
Website: https://www.piramal.com/
